Immune checkpoint inhibitor–induced hyperthyroidism: Incidence, risk factors, and clinical outcomes in a real-world cohort study
Journal of Oncology Pharmacy Practice
Published online on April 21, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundHyperthyroidism is an immune-related adverse event associated with ICI use. Its underlying risk factors, progression to thyroiditis, and impact on patient outcomes remain less understood.MethodsData were obtained from the TriNetX network for ...
BackgroundHyperthyroidism is an immune-related adverse event associated with ICI use. Its underlying risk factors, progression to thyroiditis, and impact on patient outcomes remain less understood.MethodsData were obtained from the TriNetX network for ...